However, the development of IDEC-131, another humanized monoclonal anti-CD40L, is no longer pursued after a placebo-controlled trial demonstrated no clinical activity in systemic lupus erythematosus (SLE) [43]. Here, CD40LG is linked to systemic lupus erythematosus.